Posted by Michael Wonder on 16 Nov 2021
Pfizer and the Medicines Patent Pool sign licensing agreement for COVID-19 oral antiviral treatment candidate to expand access in low and middle income countries
16 November 2021 - Agreement builds on Pfizer’s comprehensive strategy to work toward equitable access to COVID-19 vaccines and treatments for all people, particularly those living in the poorest parts of the world.
Pfizer and the Medicines Patent Pool, a United Nations-backed public health organisation working to increase access to life-saving medicines for low- and middle-income countries, today announced the signing of a voluntary license agreement for Pfizer’s COVID-19 oral antiviral treatment candidate PF-07321332, which is administered in combination with low dose ritonavir (PF-07321332; ritonavir).
